Cantley

Banking Expert Kerry Cantley Joins Mitek as VP of Digital Banking Strategy

Retrieved on: 
Thursday, June 8, 2023
Software, Finance, Banking, Data Management, Professional Services, Technology, Fintech, Security, Theft, Partnership, Federal Trade Commission, Identity theft, Intelligence, Cantley, Strategy, Capital punishment, Bank of America, FTC, Bank, Fraud, Cryptocurrency, MTX Audio

Mitek (NASDAQ: MITK), whose mission is to make digital access faster and more secure, has named experienced banking veteran Kerry Cantley Vice President of Digital Banking Strategy.

Key Points: 
  • Mitek (NASDAQ: MITK), whose mission is to make digital access faster and more secure, has named experienced banking veteran Kerry Cantley Vice President of Digital Banking Strategy.
  • Cantley brings a distinguished 30-year career in the financial services industry to Mitek.
  • Cantley is a well-known innovator and inventor in banking, with more than 30 patents related to image processes and bank operations.
  • “Mitek is trusted by 99% of U.S. banks to power and protect their mobile check deposit systems,” said Mitek CEO Max Carnecchia.

Totus Medicines Expands its Scientific Advisory Board with the Addition of Dr. Lewis Cantley, Dr. Hope Rugo, and Dr. Josep Tabernero

Retrieved on: 
Wednesday, April 12, 2023
SAB, San Francisco Bay Area, Special Program of Assisted Reproduction, AACR, SPORE, Science and technology in Asia, Vall, ESMO, American Society of Clinical Oncology, Cancer, American Association for Cancer Research, United States Air Force Scientific Advisory Board, Research, Oncology, Signal transduction, European Society for Medical Oncology, Cantley, Ioan Totu, AGIO, Harvard Medical School, ASCO, PI3K, United Nations Scientific Committee on the Effects of Atomic Radiation, Cell biology, Patient, UCSF, Drug discovery, Society, Agios Pharmaceuticals, IDeA Networks of Biomedical Research Excellence, Breast cancer, Disease, Pharmaceutical industry, Antibiotics, Medical device

To start, Totus has focused on oncology with an early breakthrough for the most mutated oncogene in cancer, PI3Kα, using the Totus Accel™ Platform.

Key Points: 
  • To start, Totus has focused on oncology with an early breakthrough for the most mutated oncogene in cancer, PI3Kα, using the Totus Accel™ Platform.
  • They include:
    Dr. Lewis Cantley : Dr. Cantley's work has helped define the field of signal transduction, and he notably discovered the PI3K pathway and its role in cancer.
  • "I am excited to join the Scientific Advisory Board of Totus Medicines.
  • The SAB advances Totus' efforts to continue to deliver unparalleled efficiency and accuracy with its groundbreaking drug discovery platform.

PHASE II CLINICAL STUDY AT WEILL CORNELL MEDICAL CENTER INVESTIGATING PAXALISIB IN COMBINATION WITH METFORMIN AND A KETOGENIC DIET ENROLLS FIRST PATIENT

Retrieved on: 
Monday, February 28, 2022
Dana, Ketosis, Cell, Glucose, Principal investigator, Fasting, Ketone, Infection, Temozolomide, New, GBM, MGMT, Diet, Joan, NASDAQ, Insulin, PI3K, Research, Therapy, Weill Cornell Medicine, National, Glioblastoma, Safety, Brain, Neurology, Cancer, Cornell University, KZIA, Protein, Progression-free survival, Cantley, Biomarker, Principal, Arm, Patient, Weill Cornell Medical Center, National Institute of Allergy and Infectious Diseases, Fats, National Institute, Metformin, Medical device, Pharmaceutical industry, Medicine, Medical imaging, Medicine

One arm of the study will examine patients with recurrent disease, and the other will enroll newly diagnosed patients.

Key Points: 
  • One arm of the study will examine patients with recurrent disease, and the other will enroll newly diagnosed patients.
  • Dr Howard Fine, founding Director of the Brain Tumor Center at New York-Presbyterian Weill Cornell Medical Center, will serve as Principal Investigator.
  • For these reasons, there is a sound rationale to explore a combination of ketogenic diet and paxalisib in glioblastoma.
  • Dr Fine is the founding Director of the Brain Tumor Center at New York-Presbyterian Weill Cornell Medical Center, Feil Professor of Medicine a Professor of Neurology at Weill Cornell Medicine.